Navigation Links
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Date:12/9/2007

LFS compared with the current standard of care, which is no treatment after successful induction of remission. The improvement in LFS achieved by Ceplene + IL-2 was highly statistically significant at three years (p=0.0096, analyzed according to Intent-to-Treat).

In patients in their first remission, there was a 55 percent improvement in LFS. This represented an absolute improvement of more than 22 weeks in terms of delayed progression of the disease. This benefit was highly statistically significant, (p=0.011). This is the intended patient population for the Marketing Authorization Application submitted for Ceplene in Europe. The results of this trial were published in "Blood," a leading scientific journal in hematology, (Blood; The Journal of the American Society of Hematology, volume 108, number 1, July 1, 2006).

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. EpiCept Corporation Announces Pricing of Public Offering
10. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
11. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Daily Gossip reveals in its review that ... that will permanently eliminate all the symptoms associated to this ... will banish symptoms such as mild hearing loss, as well ... patients will be gone forever. , The method will lead ... of this program says that at the end of the ...
(Date:7/29/2014)... 29, 2014 Daily Gossip indicates in its ... tips to gain beautiful and clear skin in just 30 ... see these positive results even sooner than that. The new ... who used this step by step program, too. , ... for years. Mike battled this condition for a decade and ...
(Date:7/29/2014)... combat injuries threatening more than one limb, reconstructive surgical ... safety and effectiveness in avoiding amputation, reports a paper ... Reconstructive Surgery , the official medical journal of ... , Experience with multiple limb salvage procedures in solders ... with no increase in complications compared to single-flap techniques, ...
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) -- Chlorine helps ... swimmers more likely to develop eye infections, doctors say. ... eyes as well as blurry vision, said Dr. Sampson ... Center in New Jersey. It,s important to understand ... pools washes away the outer film layer of the ...
(Date:7/29/2014)... According to a July 22, 2014 ... “From Kim’s Butt to Angelina’s Lips: The Plastic Surgery ... the celebrity feature most requested by women seeking cosmetic ... Jennifer Lawrence’s nose, and Angelina Jolie’s ... data collected by an online community focused on plastic ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Acne No More Review Reveals Most Effective Acne Cure Program 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2Health News:Protect Your Eyes When Hitting the Pool 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2
... Chains; 6 Receive an ,F, NEW YORK, Aug. ... your children fat? A year-long study of children,s meals ... sit-down,chain restaurants, according to the authors of the new ... and Matt Goulding calculated,calories, fat (trans- and saturated), and ...
... services for cardiovascular ... ... leader in disease prevention, announced today that the City of Tempe,Arizona ... have asthma or diabetes and are covered under the City,s PPO,Medical ...
... Current strategies can,t beat this growing challenge, researchers say ... of treating tuberculosis are failing in countries with high ... say researchers who analyzed World Health Organization data from ... countries with high rates of MDR-TB, patients are nearly ...
... that builds on healthcare reform proposal, WASHINGTON, ... today by Senators Max Baucus (D-MT) and Kent ... officer of the Blue,Cross and Blue Shield Association ... Senators Baucus and Conrad for introducing legislation that,would ...
... higher risk; doctors urged to expand education efforts , , ... at higher risk for HIV/AIDS, and doctors need to ... tested for HIV. , That,s the new recommendation released ... (ACOG). , "Rates of infection among African Americans ...
... available in <A HREF="http://www.eurekalert.org/pub_releases_ml/2008-08/aaft-t080108.php,">German . , , If someone ... change, but they don,t immediately pull off one of ... leg. With some molecules, however, the situation is quite ... seven atoms. In a charged state, the atoms arrange ...
Cached Medicine News:Health News:America's Worst Restaurants for Kids Revealed 2Health News:America's Worst Restaurants for Kids Revealed 3Health News:America's Worst Restaurants for Kids Revealed 4Health News:America's Worst Restaurants for Kids Revealed 5Health News:City of Tempe, Arizona Extends Contract with U.S. Preventive Medicine for Employee Health Management Program 2Health News:City of Tempe, Arizona Extends Contract with U.S. Preventive Medicine for Employee Health Management Program 3Health News:Drug Resistance Is Slowing Global Fight Against TB 2Health News:BCBSA: Time Is Right for Comparative Effectiveness Research Institute 2Health News:Ob/Gyn Group Urges Routine HIV Tests for All Women 2Health News:Nano sculptures in gold 2Health News:Nano sculptures in gold 3Health News:Nano sculptures in gold 4
(Date:7/29/2014)... 2014 Amgen (NASDAQ: AMGN ) ... 2014. Key results include: , Total revenues increased ... sales growth driven by strong performance across the portfolio, ... Prolia ® (denosumab) and XGEVA ® (denosumab). ... driven by higher revenues and a significant increase in ...
(Date:7/29/2014)... July 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... the Phase 3 clinical development of Revolixys™ Kit (previously ... system, today announced that it will hold a conference ... 2014, at 8:30 a.m. EDT to discuss its second ... Interested participants and investors may access the conference call ...
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 27, 2011 A milestone in lupus research was met this ... Research (ALR) held its 8th annual New York City Walk ... Park was matched by the enthusiasm of the nearly 3000 walkers ... by NYC master of ceremonies, My9 news anchor Brenda Blackmon, ALR ...
... 27, 2011   FHSSA counts its partnership initiative ... known as the Foundation for Hospices in Sub-Saharan ... between US hospice programs and organizations providing care ... assistance, support and friendship.  They are working collaboratively ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Medicine Products: